ATE446366T1 - Agonistische monoklonale antikörper gegen trkc - Google Patents

Agonistische monoklonale antikörper gegen trkc

Info

Publication number
ATE446366T1
ATE446366T1 AT01950429T AT01950429T ATE446366T1 AT E446366 T1 ATE446366 T1 AT E446366T1 AT 01950429 T AT01950429 T AT 01950429T AT 01950429 T AT01950429 T AT 01950429T AT E446366 T1 ATE446366 T1 AT E446366T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
trkc
antibodies against
agonistic monoclonal
antibodies
Prior art date
Application number
AT01950429T
Other languages
English (en)
Inventor
Brigitte Devaux
Jo-Anne Hongo
Leonard Presta
David Shelton
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE446366T1 publication Critical patent/ATE446366T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01950429T 2000-06-22 2001-06-22 Agonistische monoklonale antikörper gegen trkc ATE446366T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21314100P 2000-06-22 2000-06-22
US23831900P 2000-10-05 2000-10-05
PCT/US2001/020153 WO2001098361A2 (en) 2000-06-22 2001-06-22 Agonist anti-trk-c monoclonal antibodies

Publications (1)

Publication Number Publication Date
ATE446366T1 true ATE446366T1 (de) 2009-11-15

Family

ID=26907807

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01950429T ATE446366T1 (de) 2000-06-22 2001-06-22 Agonistische monoklonale antikörper gegen trkc

Country Status (17)

Country Link
US (4) US7384632B2 (de)
EP (1) EP1292680B1 (de)
JP (1) JP2004500873A (de)
KR (1) KR100823764B1 (de)
CN (1) CN100519749C (de)
AT (1) ATE446366T1 (de)
AU (2) AU7142201A (de)
BR (1) BR0112272A (de)
CA (1) CA2412494C (de)
DE (1) DE60140252D1 (de)
DK (1) DK1292680T3 (de)
HU (1) HU228310B1 (de)
IL (2) IL153375A0 (de)
MX (1) MXPA02012602A (de)
NZ (1) NZ523105A (de)
PL (1) PL208113B1 (de)
WO (1) WO2001098361A2 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877016A (en) * 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
DE60140868D1 (de) 2000-06-05 2010-02-04 Brigham & Womens Hospital Für ein homologes des humanen, für mehrfachresistenz verantwortlichen, p-glykoproteins auf chromosom 7p15-21 kodierendes gen sowie verwendungen dafür
ATE446366T1 (de) * 2000-06-22 2009-11-15 Genentech Inc Agonistische monoklonale antikörper gegen trkc
GB0210783D0 (en) * 2002-05-10 2002-06-19 Polonelli Luciano Anti-microbial polypeptides
US20070122852A1 (en) * 2002-11-13 2007-05-31 Micromet Ag Method for identifying antigen specific b cells
WO2004058190A2 (en) 2002-12-23 2004-07-15 Rinat Neuroscience Corp. Methods for treating taxol-induced sensory neuropathy
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1620127A4 (de) * 2003-03-20 2007-04-04 Rinat Neuroscience Corp Verfahren zur behandlung von taxol-induzierten darmstörungen
KR20070001932A (ko) * 2003-12-23 2007-01-04 리나트 뉴로사이언스 코퍼레이션 작용물질 항 티알케이씨 항체 및 그의 사용 방법
AR054260A1 (es) * 2005-04-26 2007-06-13 Rinat Neuroscience Corp Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
JP2008545781A (ja) * 2005-06-06 2008-12-18 ワイス 抗ＴｒｋＢモノクローナル抗体およびその使用
NZ596992A (en) * 2005-06-30 2013-07-26 Abbott Lab Il-12/p40 binding proteins
EP2289909B1 (de) 2005-11-30 2014-10-29 AbbVie Inc. Screeningsverfahren, Verfahren zur Reinigung von nicht-diffundierenden Beta-Oligomeren, selektive Antikörper gegen genannten nichtdiffundierende Beta-Oligomere und Verfahren zur Herstellung von genannten Antikörpern
KR101667623B1 (ko) 2005-11-30 2016-10-19 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
US20070248611A1 (en) 2006-02-02 2007-10-25 Pfizer Inc Methods wanted for treating unwanted weight loss or eating disorders by administering a trkb agonist
ES2918323T3 (es) 2006-05-31 2022-07-15 Childrens Medical Center Células madre mesenquimatosas ABC5 positivas como inmunomoduladores
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2099468B1 (de) * 2006-12-05 2018-07-11 The Royal Institution for the Advancement of Learning/McGill University Verfahren zur verwendung von trk-rezeptormodulatoren
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
EP2486928A1 (de) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Verfahren zur Behandlung von Amyloidosen
SI2155248T1 (sl) 2007-04-12 2015-12-31 The Brigham And Women's Hospital, Inc. Ciljanje ABCB5 za zdravljenje raka
US8168757B2 (en) * 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CA2724830A1 (en) * 2008-05-21 2009-11-26 Centre Leon Berard Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma
CA2952692C (en) 2008-09-22 2020-04-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds
SG10201900514RA (en) 2008-10-22 2019-02-27 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
US20110287034A1 (en) 2008-11-14 2011-11-24 The Brigham And Womens Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
KR101781228B1 (ko) 2008-12-19 2017-09-22 바이오겐 인터내셔널 뉴로사이언스 게엠베하 인간 항-알파-시누클레인 자가항체
EP2421900A1 (de) 2009-04-24 2012-02-29 Alper Biotech, Llc Monoklonale antikörper gegen pcbp-1-antigene, und anwendungen davon
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US8709424B2 (en) * 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
EP2558494B1 (de) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta-bindende proteine
BR112012029405B1 (pt) 2010-05-20 2021-01-05 Array Biopharma Inc. compostos macrocíclicos como inibidores de trk quinase, composição farmacêutica, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação de um composto
WO2012009577A2 (en) * 2010-07-14 2012-01-19 Alper Biotech, Llc Monoclonal antibodies against pcbp-1 antigens, and uses therefor
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
WO2012027821A1 (en) * 2010-09-03 2012-03-08 The Royal Institution For The Advancement Of Learning / Mcgill University A trkc receptor agonist antibody to treat neurodegenerative and motor neuron diseases
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
EP4086338A1 (de) 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Verfahren zur herstellung pluripotenter stammzellen
MX357193B (es) 2011-06-23 2018-06-29 Univ Zuerich Moleculas de union anti-alfa sinucleina.
EP2726103B1 (de) * 2011-07-01 2018-09-05 The Trustees Of The University Of Pennsylvania Antikörper gegen properdin und verwendungen davon
RU2635289C2 (ru) * 2012-05-09 2017-11-09 Конинклейке Филипс Н.В. Медицинский интерфейс слежения, обеспечивающий интервенционную информацию
CN104870474B (zh) 2012-10-04 2019-03-12 诺沃姆德治疗公司 用于治疗溶血性疾病的旁路途径特异性抗体
IL290905B2 (en) 2014-11-16 2023-09-01 Array Biopharma Inc Crystal form of (s)–n-(5–)–2–(r))5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-a]pyrimidine-3-yl)-3 -Hydroxypyrrolidine-1-carboxamide hydrogen sulfate
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
HK1253093A1 (zh) 2015-06-01 2019-06-06 Loxo Oncology Inc. 诊断和治疗癌症的方法
BR112017021484A2 (pt) 2015-06-05 2018-07-03 Novartis Ag anticorpos de direcionamento à proteína morfogenética óssea 9 (bmp9) e métodos para os mesmos
EP3322706B1 (de) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituierte pyrazol[1,5-a]pyridin-verbindungen als ret-kinasehemmer
CA2993645A1 (en) 2015-07-28 2017-02-02 Otonomy, Inc. Trkb or trkc agonist compositions and methods for the treatment of otic conditions
WO2017075107A1 (en) 2015-10-26 2017-05-04 Nanda Nisha Point mutations in trk inhibitor-resistant cancer and methods relating to the same
HUE057837T2 (hu) * 2015-11-03 2022-06-28 Janssen Biotech Inc PD-1-et specifikusan kötõ ellenanyagok és alkalmazásaik
TW201736399A (zh) 2015-12-31 2017-10-16 財團法人生物技術開發中心 抗vegfr抗體及其應用
TN2019000332A1 (en) 2016-04-04 2021-05-07 Loxo Oncology Inc Methods of treating pediatric cancers
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3439662B1 (de) 2016-04-04 2024-07-24 Loxo Oncology, Inc. Flüssige formulierungen von (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid
LT3800189T (lt) 2016-05-18 2023-10-10 Loxo Oncology, Inc. (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3- il)-3-hidroksipirolidin-1-karboksamido gavimas
CN109689027A (zh) 2016-06-29 2019-04-26 奥德纳米有限公司 甘油三酯耳用制剂及其用途
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CN110337448B (zh) * 2016-12-23 2023-08-08 瑞美德生物医药科技有限公司 使用与程序性死亡配体1(pd-l1)结合的抗体的免疫疗法
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
EP3596126A4 (de) * 2017-03-15 2021-03-03 Tsinghua University Neuartige anti-trkb-antikörper
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN111108120A (zh) * 2017-07-03 2020-05-05 财团法人生物技术开发中心 抗人类血管内皮生长因子受体的抗体及其应用
CN118370815A (zh) 2017-08-22 2024-07-23 渤健马萨诸塞州股份有限公司 含有抗β淀粉样蛋白抗体的药物组合物
EP3687546A4 (de) 2017-09-26 2022-01-26 The Trustees Of The University Of Pennsylvania Zusammensetzungen und verfahren zur behandlung von herzkrankheiten über neuausgerichtete t-zell-immuntherapien
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
AU2018346978B2 (en) * 2017-10-13 2024-02-15 Mapp Biopharmaceutical, Inc. Anti-respiratory syncytial virus antibodies, methods of their generation and use
MA50456A (fr) 2017-10-26 2020-09-02 Array Biopharma Inc Formulations d'un inhibiteur de kinase trk macrocyclique
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CA3087354C (en) 2018-01-18 2023-01-03 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CA3095366A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
KR102653681B1 (ko) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
EP3898615A1 (de) 2018-12-19 2021-10-27 Array Biopharma, Inc. 7-((3,5-dimethoxyphenyl)amino)chinoxalin-derivate als fgfr-inhibitoren zur behandlung von krebs
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
EP4034554A4 (de) * 2019-09-23 2023-10-25 The Trustees of the University of Pennsylvania Zerstörung von tumorgewebe durch targeting von fibroblasten-aktivierungsprotein (fap)
EP4041290A4 (de) 2019-09-23 2024-02-07 The Trustees of the University of Pennsylvania Monoklonaler antikörper gegen fibroblasten-aktivierungsprotein des hundes, das mit fibroblasten-aktivierungsprotein (fap) der maus und des menschen kreuzreagiert
CN117447602B (zh) * 2023-12-22 2024-03-19 北京索莱宝科技有限公司 猪IgM的抗体及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL95511A (en) * 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
CA2040099A1 (en) 1990-05-01 1991-11-02 Mariano Barbacid Tyrosine kinase negative trkb
US5364769A (en) 1990-09-25 1994-11-15 Genentech, Inc. Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production
US5348856A (en) 1991-07-08 1994-09-20 E. R. Squibb & Sons, Inc. DNA encoding TRKC protein
ATE206056T1 (de) 1992-06-08 2001-10-15 Takeda Chemical Industries Ltd Therapeutisches agens für neutropenie
US5855885A (en) * 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US5659791A (en) * 1993-04-26 1997-08-19 Microsoft Corporation Encapsulation of extracted portions of documents into objects
WO1995014930A1 (en) 1993-11-23 1995-06-01 Genentech, Inc. Kinase receptor activation assay
CA2175893C (en) 1993-11-23 2010-06-22 Paul J. Godowski Protein tyrosine kinases named rse
US5753225A (en) 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
US5877016A (en) * 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
JPH07285912A (ja) * 1994-04-19 1995-10-31 Asahi Chem Ind Co Ltd 新規化合物ａｍ５２２１
WO1996036361A1 (en) * 1995-05-18 1996-11-21 The Regents Of The University Of Michigan Dna binding antibodies
US6018032A (en) * 1995-09-11 2000-01-25 Kyowa Hakko Kogyo Co., Ltd. Antibody against human interleukin-5-receptor α chain
GB9525180D0 (en) * 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
EP0977860A1 (de) * 1997-04-25 2000-02-09 Genentech, Inc. Ngf variante
EP1126869B1 (de) 1998-10-28 2008-09-03 Cornell Research Foundation, Inc. Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4
US6656474B1 (en) * 1999-01-15 2003-12-02 Regeneron Pharmaceuticals, Inc. Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
ATE446366T1 (de) * 2000-06-22 2009-11-15 Genentech Inc Agonistische monoklonale antikörper gegen trkc

Also Published As

Publication number Publication date
PL208113B1 (pl) 2011-03-31
DK1292680T3 (da) 2010-03-08
PL359926A1 (en) 2004-09-06
US7384632B2 (en) 2008-06-10
US7615383B2 (en) 2009-11-10
HUP0300841A2 (hu) 2004-06-28
CA2412494A1 (en) 2001-12-27
IL153375A (en) 2009-06-15
EP1292680B1 (de) 2009-10-21
MXPA02012602A (es) 2003-05-14
CA2412494C (en) 2012-10-23
CN100519749C (zh) 2009-07-29
WO2001098361A9 (en) 2003-03-06
WO2001098361A3 (en) 2002-05-02
US20040137513A1 (en) 2004-07-15
US20070036794A1 (en) 2007-02-15
KR20030036240A (ko) 2003-05-09
EP1292680A2 (de) 2003-03-19
BR0112272A (pt) 2003-05-06
HU228310B1 (en) 2013-03-28
US20100003261A1 (en) 2010-01-07
AU2001271422B2 (en) 2005-12-22
HUP0300841A3 (en) 2005-11-28
DE60140252D1 (de) 2009-12-03
KR100823764B1 (ko) 2008-04-21
CN1447857A (zh) 2003-10-08
JP2004500873A (ja) 2004-01-15
WO2001098361A2 (en) 2001-12-27
IL153375A0 (en) 2003-07-06
NZ523105A (en) 2004-07-30
AU7142201A (en) 2002-01-02
US20120045443A1 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
ATE446366T1 (de) Agonistische monoklonale antikörper gegen trkc
BR0011838B1 (pt) elemento de sela e estrutura de misturador estático.
NI200800032A (es) Reducción de célula b utilizando moléculas de unión específicas cd37 y cd20
TNSN08255A1 (en) Anti-mn antibodies and methods of using same
EP1844077A4 (de) Dr5-antikörper und deren verwendung
ATE515288T1 (de) Carboxy-amido-triazole zur lokalisierten behandlung von augenerkrankungen
TW200635608A (en) Aβ antibodies for use in improving cognition
TW200635607A (en) Humanized Aβ antibodies for use in improving cognition
ATE476495T1 (de) Bazillus thuringiensis und dessen insektizide proteine
EP1700120A4 (de) Marker für neuromyelitis optica
GEP20043349B (en) Methods of Controlling Cutworm Pests
SG166768A1 (en) Agonist anti-trkc antibodies and methods using same
ATE389670T1 (de) Selektive peptidische agonisten des vpac2- rezeptors
WO2004083241A3 (en) Btc-interacting proteins and use thereof
BRPI0508084A (pt) método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo
ATE494307T1 (de) Neoplasma-spezifische antikörper und deren verwendungen
EP0929217A4 (de) Sordarinderivate
EP1007032A4 (de) 4-cyano-4-deformylsordarizin-derivate
ATE412010T1 (de) Selektive peptidische agonisten des vpac2- rezeptors
DE602006018461D1 (de) Galk1s als modifikatoren des pten/akt-wegs
EP1007031A4 (de) 4-cyano-4-deformylsordarinderivate
WO2005046617A3 (en) Compositions and methods for reducing microbial induced apoptosis
WO2004019880A3 (en) Aw755252-interacting proteins and use thereof
WO2003023048A3 (en) METHODS FOR DIAGNOSING AND TREATING DISEASES AND CONDITIONS ASSOCIATED WITH PROTEIN KINASE C$g(l)
DE602006016952D1 (de) Cnf1 bacterielles toxin-protein aus e. coli als analgetikum

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties